Ligand validation:4EYR

RIT: RITONAVIR

RIT is a Ligand Of Interest in 4EYR designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
4EYR_RIT_B_301	3%	33%	0.415	0.744	1.08	1.54	3	11	25	0	100%	0.5
2B60_RIT_B_100	35%	13%	0.186	0.874	1.82	2.15	6	10	4	0	100%	0.5
4NJV_RIT_A_500	34%	11%	0.187	0.869	2.25	1.9	11	13	6	0	100%	0.5
1SH9_RIT_B_301	21%	7%	0.26	0.871	2.16	2.62	16	13	13	0	100%	0.6
3PRS_RIT_A_1001	93%	40%	0.071	0.967	0.99	1.32	2	7	3	0	100%	0.979
3NDX_RIT_A_100	69%	24%	0.117	0.931	1.06	2.05	4	19	1	0	100%	0.91
3NDW_RIT_A_100	57%	27%	0.135	0.909	1.01	1.91	3	14	0	0	100%	0.91
3NXU_RIT_A_600	55%	1%	0.144	0.913	5.85	3.07	34	25	4	0	100%	1
7VE0_RIT_A_401	51%	39%	0.137	0.89	0.95	1.42	2	7	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.